Drugs / ECF843
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04391894 | Oct 2020 → May 2021 | dry eye syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-04-06 | Novartis Pharmaceuticals | Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECF843 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04391894 ↗ |
| Route | Topical | “Topical ocular eye drop” NCT04391894 ↗ |